Gentamicin Therapy Guidelines

Introduction to Gentamicin Therapy

• The recommended 24-hour dose of gentamicin for adults with serious infections and normal renal function is 3-5 mg/kg/day, typically administered in three equally divided doses every 8 hours, as recommended by the American Heart Association 1

Endocarditis Treatment

• For native valve endocarditis, the American Heart Association recommends a gentamicin dose of 3 mg/kg/day divided every 8 hours, and for prosthetic valve endocarditis, a gentamicin dose of 3 mg/kg/day divided every 8 hours is recommended for the first 2 weeks 1, 2
• For enterococcal endocarditis, a gentamicin dose of 3 mg/kg/day divided every 8 hours is recommended for 4-6 weeks, with traditional multiple daily dosing preferred over once-daily dosing for serious infections like endocarditis 2, 1, 3

Treatment Duration and Dosing Regimens

• The treatment duration for endocarditis is 4-6 weeks, depending on the organism and valve type, with the following gentamicin dosing regimens recommended by the American Heart Association:

  Indication	Dose	Duration
  Native valve endocarditis caused by viridans group streptococci	3 mg/kg/day IV/IM in 1 dose or 3 equally divided doses	2 weeks
  Prosthetic valve endocarditis caused by staphylococci	3 mg/kg/day IV/IM in 2-3 equally divided doses	2 weeks

  4, 3

• Gentamicin dosing adjustments should be based on creatinine clearance, with a dose of 3 mg/kg/day for serious infections in patients with normal renal function, and once-daily dosing (4 mg/kg once daily) may be preferred for most patients with normal renal function due to potentially reduced nephrotoxicity 4, 5

Renal Function Considerations

• The American Heart Association and other societies recommend assessing baseline renal function before initiating potentially nephrotoxic medications, considering patient-specific risk factors, and avoiding combinations of nephrotoxic medications in patients with impaired renal function 6, 3
• The American College of Clinical Pharmacy and the European Renal Association recommend adjusting medication doses based on estimated glomerular filtration rate (eGFR) or creatinine clearance, using the lowest effective dose for the shortest duration necessary, and considering extended dosing intervals rather than reduced doses for some medications, such as aminoglycosides, in patients with impaired renal function 6, 7

Monitoring and Toxicity Prevention

• The American Society of Health-System Pharmacists recommends monitoring serum drug levels, targeting peak levels of 4-6 mcg/mL and trough levels of <2 mcg/mL to minimize toxicity, and monitoring renal function regularly, including serum creatinine, BUN, and electrolytes, in patients receiving aminoglycosides 8
• The American Heart Association recommends avoiding gentamicin if possible in patients with creatinine clearance <20 mL/min, and consulting with an infectious disease specialist for individualized dosing if necessary, with therapeutic drug monitoring essential for courses >3 days, especially in patients with fluctuating renal function 4, 9

Special Populations

• The American Geriatrics Society and the National Institute on Aging recommend using lower doses of aminoglycosides, such as 10 mg/kg/day, in elderly patients (>59 years) and considering alternative non-nephrotoxic medications when possible, with therapeutic drug monitoring to guide dosing due to altered pharmacokinetics and higher risk of AKI 8
• The American College of Rheumatology and the National Kidney Foundation recommend using the lowest effective dose of NSAIDs for the shortest duration, monitoring renal function regularly, and ensuring adequate hydration in patients with mild renal impairment, and generally avoiding NSAIDs in patients with moderate to severe renal impairment 6

Hydration and Nephrotoxicity Prevention

• The Society of Critical Care Medicine and the American Society of Nephrology recommend ensuring adequate hydration before and during therapy with nephrotoxic medications, considering IV hydration for high-risk patients receiving contrast agents or aminoglycosides, and allowing >24 hours between doses of nephrotoxic agents when possible, and administering aminoglycosides after dialysis sessions in patients on dialysis 7, 8